Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$86.88 USD
+2.51 (2.97%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $86.88 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
LGND 86.88 +2.51(2.97%)
Will LGND be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for LGND based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LGND
Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer
Gilead (GILD) Up as Twice-Yearly HIV Shot Prevents Infection
LGND: What are Zacks experts saying now?
Zacks Private Portfolio Services
Roche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics
Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue?
Roche (RHHBY) Reports Upbeat Data on Columvi From STARGLO Study
Other News for LGND
Ligand Pharma’s Growth Outlook Bolstered by COPD Drug Approval and Strategic Oncology Royalty Deal
Craig-Hallum Sticks to Their Buy Rating for Ligand Pharma (LGND)
Ligand earns $5.8M milestone payment following FDA approval of Ohtuvayre
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults
Ligand collaborator Merck receives FDA approval for CAPVAXIVE